January 31st, 2014
Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.
Non-24 was first described more than 60 years ago, and is a chronic, circadian rhythm disorder resulting from the misalignment of the endogenous master body clock to the 24-hour day, disrupting the sleep-wake cycle. Non-24 affects the majority of totally blind individuals and it is estimated that approximately 80,000 Americans have the disorder.
The approval of HETLIOZ was based on two key efficacy studies and the safety has been evaluated in over 1,300 individuals.
The most common adverse reactions in the clinical trials were headache, increased alanine aminotransferase, nightmares or unusual dreams, upper respiratory or urinary tract infection. After taking HETLIOZ, patients should limit their activity to preparing for going to bed because HETLIOZ can impair the performance of activities requiring complete mental alertness.
Vanda anticipates making HETLIOZ commercially available in the second quarter of 2014.
See the full press release here.
Connect with us on Google.